Objectives: We report the synthesis, antibacterial activity and toxicity of 24 bis-indolic derivatives obtained during the development of new ways of synthesis of marine bis-indole alkaloids from the spongotine, topsentin and hamacanthin classes.
Introduction
Since the discovery of penicillin G in the early 1940s, antibiotics have become the cornerstone of treatment of bacterial infections. 1 However, despite the development of numerous antibiotic classes, multidrug resistance to antibiotics now occasionally leads to therapeutic impasses, 2, 3 especially in hospital settings where bacteria face high antibiotic selection pressure. Among MDR bacteria, Staphylococcus aureus is able to resist antibiotics through several mechanisms: (i) the production of enzymes that inactivate antibiotics (e.g. penicillinase and transferases); (ii) the modification of natural targets of antibiotics, as observed for the mecA gene that codes for a novel PBP (PBP2a) resistant to the action of almost all b-lactams in MRSA strains; and (iii) the overproduction of efflux systems such as the multidrug NorA efflux pump involved in resistance to quinolones and fluoroquinolones. 4 -6 Antibiotic treatment of infections caused by S. aureus strains with acquired resistance to the first-line antistaphylococcal drugs, especially b-lactams (MRSA strains) and glycopeptides [vancomycin-intermediate S. aureus (VISA) strains and vancomycin-resistant S. aureus strains], is highly challenging. Moreover, infections caused by MRSA strains or S. aureus strains with reduced susceptibility to vancomycin (MIC .1 mg/L) are associated with a poorer outcome. 7, 8 There is an urgent need to develop new drugs active against these MDR S. aureus strains.
Over the last six decades, the search for new antibiotic compounds has been supported by the pharmaceutical industry, with continuous development of new drugs derived from known antibiotic classes. Because of similar structural features between old and new compounds, resistance to the latter has rapidly emerged. Therefore, pharmaceutical companies have currently lost interest in this therapeutic field, 3, 9 owing to the poor return on investments. This is particularly true for Gram-negative MDR bacteria, whereas several anti-MRSA agents are still in the pipeline. 10 Measures to overcome bacterial resistance to antibiotics may include three complementary approaches: (i) preserve the antibiotic activity of the more recently developed molecules by optimizing their use in humans and animals; (ii) inhibit known bacterial resistance mechanisms in order to restore the activity of inactivated antibiotics; and (iii) develop novel compounds active against MDR bacteria, ideally displaying original chemical structures, in order to delay the emergence of new resistance mechanisms. 2 Since the 1970s, only two new antibiotic classes have been developed and approved: 1, 11 the oxazolidinones (e.g. linezolid, Pfizer), which inhibit protein synthesis by binding to the peptidyl transferase centre of the bacterial ribosome; 12 and the lipoglycopeptides (e.g. daptomycin, Cubist Pharmaceuticals), which act through membrane depolarization and disturbance of membrane-associated processes, leading to bacterial cell death. 13, 14 Unfortunately, resistance mechanisms to these two antibiotic classes have already emerged in Staphylococcus strains. 15, 16 Because most currently available antibiotics were first extracted from terrestrial microorganisms during the last two decades, the search for original bioactive molecules has focused on marine bio-organisms. Among them, sponges appear to be one of the richest phyla in toxicogenic species because of their ability to produce a wide variety of secondary metabolites. In particular, bis-indole alkaloids have shown cytotoxic, antitumoral, antiviral, antiparasitic, antifungal, anti-inflammatory and antibacterial activities. 17 These molecules present unique structures with two indole units linked either by an imidazole or a piperazine core. Indeed, the central linker is an a-carbonylimidazoline for spongotines, an a-carbonylimidazole for topsentins and a 5,6-dihydropyrazinone for hamacanthins A (Figure 1 ; molecules 1, 2 and 3, respectively). 17 -19 The search for innovative methods of chemical synthesis of spongotines, topsentins and hamacanthins highlighted that these molecules include the 1-(1H-indol-3
′ -yl)-1,2-diaminoethane unit 4 ( Figure 1) . 20, 21 This common key scaffold is not easily accessible via conventional synthetic methodologies. We developed an original access to the first derivatives of this key unit, using a reaction between an a-amino nitrone and the appropriate indolic core, paving the way to spongotines, topsentins and hamacanthins A. 20, 21 These innovative protocols led to a large number of original structures, sharing either an indolic or a bis-indolic scaffold. 18 In the meantime, compounds of DCM's chemical library were screened against various biological targets, including bacterial strains, in order to evaluate their potential activities. Owing to the great diversity of compounds of this chemical library, the chances of finding bioactive molecules were increased. Indeed, mono-indolic molecules with intrinsic antibacterial activity against S. aureus and other Staphylococcus species or inhibiting the S. aureus NorA multidrug efflux pump were discovered. 18,20 -23 Due to their original structures and antibacterial activities, these compounds were patented 24 and further structural optimizations allowed us to obtain new molecules with a bis-indolic scaffold linked either by an amide or an a-keto-amide group. 25, 26 This study reports the original ways of synthesis, antistaphylococcal activities, physicochemical properties and cytotoxicity of these new families of bis-indolic compounds.
Materials and methods

Synthetic derivatives
Twenty-four bis-indolic molecules were synthesized (Table 1 as well as the  Supplementary data, available Caspar et al.
described in the Supplementary data. Then, stock solutions of these compounds were prepared by diluting powders in pure DMSO (Sigma-Aldrich, Saint-Quentin Fallavier, France) at a concentration of 25.6 g/L. Working solutions of the bis-indolic compounds were prepared in bacterial growth medium so as to obtain final concentrations of DMSO ,5%, which was verified to be non-toxic for the bacterial strains tested. Staphylococcus warneri. Identification at the species level for these clinical strains was obtained by amplification and sequencing of the tuf gene according to previously published protocols. 27 The fluoroquinolone-resistant S. aureus SA-1199B strain, which overexpresses the chromosomal norA gene encoding the NorA efflux pump and also harbours an A116E mutation in grlA, 28 was generously provided by G. W. Kaatz (University of Michigan). This strain displays a ciprofloxacin MIC of 16 mg/L, whereas its parental counterpart (SA-1199) has an MIC of 0.25 mg/L.
Bacterial strains
Determination of MICs
MICs of the 24 bis-indolic compounds were determined for all S. aureus strains described above except MSSA476 and MRSA252 and for S. epidermidis strains ATCC 12228, CIP 81.55 and CIP 103627. A broth microdilution method was used, as recommended by the CLSI (M07-A8) using Mueller-Hinton 2 (MH2) broth (bioMérieux, Marcy-l'Étoile, France) as the experimental medium. For all those bacterial strains, two rows of a 96-well microtitre plate were filled with a bacterial inoculum (180 mL per well, 5×10
5 cfu/mL of final inoculum) and 20 mL of 2-fold serial dilutions of a stock solution of the tested bis-indolic compound in MH2 broth with 10% DMSO, so as to obtain final concentrations ranging from 0.5 to 128 mg/L. For some of the compounds, antibiotic suspensions at 64 and 128 mg/L were cloudy, suggesting that the solubility limit was reached and the antibiotic concentration could have been overestimated. Drug-free cultures served as growth controls. Cultures containing DMSO at final concentrations found in working solutions of the tested bis-indolic compounds were used as DMSO toxicity controls. Microplates were incubated at 378C in ambient air. MICs were read after 24 h of culture incubation and corresponded to the minimum concentration of the bis-indolic compound that allowed complete inhibition of visual growth of bacteria. The determined MICs of ciprofloxacin and gentamicin were used as positive controls. Experiments were performed at least twice for each bis-indolic compound to confirm results.
MICs of three lead compounds for a large number of Staphylococcus species
A second assay was built in order to evaluate the activity of three lead compounds (9f, 17c and 17d) against a larger number of Staphylococcus species. To improve the solubility of the bis-indoles at high concentrations, two rows of a 96-well microtitre plate were filled with a bacterial inoculum (192 mL per well, 5×10 5 cfu/mL of final inoculum) and 2-fold serial dilutions of the tested bis-indolic compound in pure DMSO (8 mL per well) so as to obtain final concentrations ranging from 0.5 to 32 mg/L, with ,5% DMSO. Growth controls and DMSO toxicity controls were added as previously described. The antistaphylococcal activity of lead compounds was determined against seven reference strains, including the previously tested S. aureus ATCC 106414, S. aureus SA-1199B and S. epidermidis ATCC 12228 strains, taken as controls, and strains MSSA476, MRSA252, S. epidermidis ATCC 49461 and S. sciuri ATCC 29061. We also tested 39 clinical strains belonging to different Staphylococcus species. Microplates were incubated at 378C in ambient air and MICs were read after 24 h of incubation. For each experiment, we checked that MICs obtained for the control strains were within 0.5 -2× expected MICs. Experiments were conducted at least in duplicate for each strain.
Evaluation of plasma protein binding using MIC protocols
To seek potential plasma protein binding of our lead compounds, 9f, 14a, 17c and 17d, the MICs were determined (using the second protocol described above) for the S. aureus ATCC 29213 strain in the presence of 0%, 1%, 5% or 10% of decomplemented FCS (Gibco w , Life Technologies, Saint Aubin, France). The bis-indole derivatives were tested at concentrations ranging from 0.03 to 32 mg/L. Gentamicin (0.03-16 mg/L) was used 
Determination of MBCs
MBCs were determined for the lead compounds 10a, 14a and 17d and gentamicin (control) for S. aureus ATCC 29213 according to the CLSI (formerly NCCLS) M26-A microdilution procedure. 29 Briefly, a protocol closely related to MIC determination was applied, except that the primary inoculum was prepared from bacterial cultures in the logarithmic phase of growth. After 24 h of incubation of the plates at 378C in ambient air, the MBCs were determined after stirring by inoculation of 10 mL of the bacterial suspension from each well with no visible growth (concentration ≥MIC) on MH2 agar plates (bioMé rieux). cfu counts were determined after 24-48 h of incubation of the plates at 378C in ambient air and compared with CLSI M26-A tables. The MBC corresponds to the minimum antibiotic concentration that results in ≥99.9% reduction of the primary bacterial load (i.e. 3 log 10 reduction of bacterial titres). MBC experiments were conducted in triplicate to confirm results.
Determination of time -kill curves
Time-kill curves were measured for the lead compounds 9f, 10a, 14a, 17c and 17d against S. aureus ATCC 29213 and ATCC 25923 according to the CLSI M26-A procedure. 29 For each S. aureus strain, an overnight culture in MH2 broth was adjusted to a turbidity equivalent to that of a 0.5 McFarland standard. Then, 100 mL of this suspension was added to 10 mL of MH2 broth (pre-warmed to 378C). This mixture was incubated at 378C for 4 h before being diluted to 1/65 in 40 mL of pre-warmed MH2 broth, so as to obtain 5×10 5 cfu/mL of a primary inoculum. The primary inoculum was split into seven 5 mL aliquots in glass tubes, one serving as an antibiotic-free growth control (containing 4% DMSO) and the six others receiving, respectively, 9f, 10a, 14a, 17c, 17d (in 4% DMSO) or gentamicin (with no DMSO) at eight times their respective MIC for the tested strain. Sterile MH2 broth with 4% DMSO served as a sterility control. Cultures were incubated for 24 h at 378C. At 0, 2, 4, 8 and 24 h of incubation, a 50 mL aliquot was taken from each culture after shaking. Then, 50 mL of 10-fold serial dilutions in MH2 broth of each aliquot were plated onto MH2 agar plates. cfu counts were determined after 24 -48 h of incubation of the plates at 378C in ambient air. A significant bactericidal effect corresponded to a ≥3 log 10 reduction of the primary bacterial inoculum at any time of incubation. For compound 17d, we repeated the experiment at 2×, 4× and 8× MIC for S. aureus ATCC 29213 and ATCC 25923 strains to test for concentration-dependent time -kill kinetics. All time -kill kinetics assays were performed in triplicate. The results are expressed as the mean of the three replicates+SD. The statistical significance of the reduction of cfu counts compared with the primary inoculum was determined at various exposure times of bacteria to the bis-indoles or gentamicin, using a one-tailed Student's t-test and a P value ,0.05.
Because we observed bacterial regrowth at 24 h incubation time, we checked the presence of resistant mutants in the cultures exposed to 17d at 2×, 4× and 8× MIC. Subcultures (50 mL) were performed on MH2 and the bacterial colonies obtained were tested for 17d MICs (two replicates per subculture) at the same time as the reference strains.
Determination of single-step resistance frequency
The frequency of spontaneous mutants resistant to one of the three lead compounds (9f, 17c and 17d) was determined in duplicate experiments. A bacterial suspension (10 9 -10 10 cfu/mL) of MSSA476 or MRSA252 was inoculated (100 mL) onto MH2 agar plates containing 4×, 8× or 16× MIC of the bis-indolic compound tested. After 48 h of incubation of the plates at 378C in ambient air, the colonies were counted. We confirmed that the isolated colonies corresponded to resistant bacteria by determination of their MICs using the broth microdilution method. Resistance was defined as an MIC that was ≥4× MIC for the parental strain. The frequency of single-step resistance to a given compound was calculated by the ratio of the number of confirmed resistant colonies to the total number of colonies obtained in a drug-free control.
Physicochemical analysis
Measurements of solubility, the chromatographic hydrophobicity index (CHI; which estimates the log D and thus the hydrophobicity of compounds) and plasma protein binding were conducted for compounds 9f, 14a, 14c, 17c and 17d at TechMed ILL (ESBS, Illkirch, France) according to previously published protocols. 30, 31 For complete details, refer to www. pcbis.fr and the Supplementary data.
All solubility, CHI and plasma protein-binding assays were performed in duplicate. Results are expressed as the mean+SD.
Determination of NorA efflux pump inhibition
Compounds showing no intrinsic antibacterial activity were the only ones to be tested for NorA efflux pump inhibition. This activity was determined for four bis-indolic compounds (9a, 12, 14b and 17a) by testing their capacity to restore the activity of ciprofloxacin against the SA-1199B strain. Various concentrations of the bis-indolic compounds were tested in combination with three different subinhibitory concentrations of ciprofloxacin: 4 mg/L (MIC/4), 2 mg/L (MIC/8) or 1 mg/L (MIC/16). For each combination, the minimum concentration of the bis-indolic compound that restored the bacteriostatic activity of ciprofloxacin due to NorA efflux pump inhibition was recorded as the epi-MIC.
Bis-indolic compounds were dissolved in DMSO at 10 mg/mL and then further diluted in MH2 broth. A 96-well microplate was filled with a SA-1199B suspension at 10 6 cfu/mL. Using a Biomek 2000 handling robot (Beckman Coulter, Villepinte, France), the bis-indolic compounds were dispensed so as to obtain final 2-fold serial concentrations ranging from 0.125 to 128 mg/L. For each bis-indolic concentration tested, ciprofloxacin was added at a final concentration of 4, 2 or 1 mg/L, respectively. Bacterial growth was determined both visually and using a microplate reader at a 620 nm absorption wavelength, after 24 h of incubation of the plates at 378C. Cultures free of bis-indolic compounds but containing 5 mL of DMSO were used as growth controls. Positive controls included subinhibitory (4 mg/L) and inhibitory (64 mg/L) concentrations of ciprofloxacin for SA-1199B. All experiments were performed in duplicate.
Cytotoxicity determination
The in vitro cytotoxicity of 20 bis-indolic compounds (9a-k, 10a, 12, 14a-c and 17a-d) was assayed on three different cell lines: KB (human mouth carcinoma), MCR5 (human lung fibroblast) and HCT116 (human colon tumour) (Table S1 ). Cell monolayers were prepared in 96-well tissue culture microplates and grown in 200 mL of complete medium for 24 h. Then, using a Biomek 3000 apparatus (Beckman-Coulter), 2 mL of a stock solution in DMSO of the bis-indolic compound tested was added to the cell culture supernatant to obtain a final concentration of 10 25 or 10 26 M. Cell cultures free of bis-indolic compound but with the same concentration of DMSO (1% of final volume) served as DMSO toxicity controls. After 72 h of incubation of cell cultures, MTS reagent (Promega, Lyon, France) was added and incubated for 3 h at 378C. Absorbance at 490 nm of aqueous soluble formazan product was monitored and the results were expressed as the percentage of cellular growth inhibition calculated according to the [12(OD 490 treated/ OD 490 control)]×100 ratio, determined in triplicate experiments. In a separate experiment, using a similar protocol, the IC 50 (i.e. the concentration of compound inhibiting 50% of cellular growth) was determined in duplicate against the HCT116 cell line for compounds 9b, 9c, 9f, 9g, 9h, 9i, 9j, 10a, 12, 15c, 17c and 17d, tested at concentrations ranging from 0.005 to 100 mM ( Table 2) .
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Results
Synthesis of bis-indolic compounds
The structures of the bis-indolic compounds synthesized are original compared with those of natural alkaloids, especially those found in marine sponges. Twenty-four bis-indolic molecules, including 20 with an amide group linker (9a-k, 10a,  10b, 12, 14a -c and 15a -c) and four with an a-keto-amide linker (17a -d), were prepared (Table 1 and Figures S1 -S6 ; see the Supplementary data for complete synthesis details). The synthesis of two of them (17a and 17b) was previously described. 20 Lead bis-indolic compounds exhibit potent antistaphylococcal activity, including against MDR S. aureus strains MICs of the 24 bis-indolic compounds were determined for 10 reference S. aureus strains including two MRSA strains and one VISA strain and for three reference S. epidermidis strains including a methicillin-resistant strain. Four derivatives (9a, 12, 14b and 17a) had no proper antibacterial activity against any of the bacterial strains tested. In contrast, the remaining 20 compounds were active against all Staphylococcus strains (Table 2) . However, MICs ranged from 1 to 32 mg/L for the various compounds, the most active being 9f, 9g, 9h, 9i, 17c and 17d, with MICs ranging from 1 to 2 mg/L. Interestingly, MICs of the different bis-indolic compounds remained unchanged when testing S. aureus strains resistant to currently available antibiotics, including b-lactams (MRSA strain), glycopeptides (VISA strain) and fluoroquinolones (SA-1199B strain). For the three lead compounds 9f, 17c and 17d, we further tested one MSSA, one MRSA and 41 CoNS strains belonging to 12 different species (Table 3 ). All these strains were susceptible to 9f, 17c and 17d with MICs of 1 -4 mg/L.
MBCs and time -kill studies revealed early bactericidal activity followed by bacterial regrowth
The bactericidal activity of bis-indoles was evaluated by time -kill kinetic studies for compounds 9f, 10a, 14a, 17c and 17d against S. aureus ATCC 29213 and ATCC 25923 strains (Figure 2a and b) . A significant reduction in cfu counts was found for all compounds against both strains and a 3 log reduction of cfu counts was found for compounds 10a, 14a and 17d after 8 h of culture incubation. We then observed bacterial regrowth after 24 h of culture incubation. In contrast, MBC determination revealed that compounds 10a, 14a and 17d allowed a 99.9% reduction of the initial bacterial load (5×10 5 cfu/mL) after 24 h of incubation for S. aureus ATCC 29213 strain at 8, 8-16 and 16 -32 mg/L, respectively. For compounds 9f and 17c, time-kill kinetics only revealed a 1 -2-fold reduction of cfu counts within the first 4 -8 h of incubation.
For compound 17d, time -kill kinetics were also performed at 2×, 4× and 8× MIC for S. aureus ATCC 29213 and ATCC 25923 strains in order to distinguish time-dependent from concentrationdependent bactericidal activity. As shown in Figure 2(c and d) , 17d displayed a concentration-dependent bactericidal effect, with again a maximum activity after 8 h of culture incubation. 
Antibacterial evaluation of bis-indolic derivatives
Bacterial regrowth was observed at 24 h incubation time, but MICs determined for selected colonies obtained from these bacterial populations revealed no selection of resistance to 17d. MICs for subcultured bacteria were the same as those for the parental S. aureus strains (i.e. 2 mg/L).
No resistant mutants were selected by the single-step resistance selection study
Spontaneous resistance frequency was determined in duplicate for the three lead compounds (9f, 17c and 17d) against one MSSA strain and one MRSA strain. Although rare colonies had grown after 24 h of incubation of bacterial suspensions on MH2 agar plates containing 4×, 8× or 16× MIC for the corresponding S. aureus strain, none of them corresponded to resistant mutants, as confirmed by MIC determination. Thus, spontaneous singlestep resistance frequencies were ,10 29 for the three compounds tested against both MSSA and MRSA strains.
Evaluation of plasma protein binding and physicochemical analysis of lead compounds revealed high hydrophobicity, poor solubility and high plasma protein binding
To better guide further structural optimization and apprehend protein binding of our synthetic bis-indole compounds, the effect of 1% -10% decomplemented FCS on MIC values was evaluated for lead compounds 9f, 14a, 17c and 17d. Overall, a 1 -16-fold When MICs were split between two or more dilutions, the mode value is indicated in bold.
increase in MIC values was observed when adding 1% -10% FCS ( Table 4 ), meaning that these lead compounds probably strongly bind to plasma proteins. To confirm these results and further evaluate the physicochemical properties of the lead derivatives, the exact protein-binding percentage was measured as well as solubility at physiological blood pH and estimated log D via CHI determination. As expected, the solubility of the lead compounds ranged from only 1.2 to 30.3 mM at pH 7.4, log D was between 2.61 and 4.03 and the whole fraction of our compounds was bound to plasma protein when tested at 100 mM ( Table 5) .
Determination of inhibitory activity of the multidrug efflux pump NorA
The four bis-indolic derivatives 9a, 12, 14b and 17a, showing no intrinsic antibacterial activity against S. aureus strains ATCC 25923 and SA-1199B (i.e. MIC .32 mg/L), potentiated ciprofloxacin activity against S. aureus SA-1199B. The ciprofloxacin MIC for SA-1199B was reduced 4-fold (from 16 to 4 mg/L) when this antibiotic was tested in combination with 32 mg/L of compound 14b, but only 0.25 mg/L of compounds 9a or 12 (Table 6 ). Compound 17a, a bis-indolic derivative possessing an a-keto-amide linker, decreased the ciprofloxacin MIC to 4 and 2 mg/L for SA-1199B when tested at 0.5 and 2 mg/L, respectively. The non-brominated derivatives 9a and 17a were therefore as efficient as the methylated indole compound 12. The latter derivative had no proper antibacterial activity against SA-1199B, whereas its nonmethylated analogue 9f displayed a 2 mg/L MIC for this strain.
Thanks to the presence of the carboxylic function, compound 14b was completely soluble whilst inactive at 128 mg/L when used alone. However, higher concentrations of compound 14b were necessary to significantly decrease the ciprofloxacin MIC.
In the presence of 1 mg/L of ciprofloxacin, as high as 128 mg/L compound 14b was necessary to inhibit bacterial growth.
Structure-activity relationship (SAR) study
We tried to determine the pharmacophore involved in the antistaphylococcal activity of the bis-indolic compounds (see the Supplementary data for detailed SAR analysis). In summary, the most effective compounds contained in their structure two indole cores with a free indolic nitrogen, with either an amide or an a-keto-amide linker, each indolic core carrying one bromine atom at position 5 or 6. However, higher antibacterial activity correlated with increased cytotoxicity for many compounds.
Discussion
The search for efficient therapeutic alternatives against MDR bacteria, and more specifically MRSA strains, is a scientific and medical priority. 2, 8, 32 Various marine invertebrates including bryozoans, coelenterates, tunicates and sponges synthesize indole-containing alkaloids. 18, 19 Among them, bis-indole alkaloids from the spongotine, topsentin and hamacanthin classes were isolated from many sponge species, including Topsentia sp., Hamacantha sp., Spongosorites sp. and Rhaphisia lacazei. 18,19,33 -37 Previous studies have shown that these compounds are active against various bacterial species, including Bacillus subtilis, Micrococcus luteus, MSSA, MRSA, Proteus vulgaris and Salmonella enterica Typhimurium, but not Escherichia coli. 19, 38 The most active compounds were deoxytopsentin, bromotopsentin, hamacanthin A, trans-4,5-dihydrohamacanthin A, hamacanthin B and 6 ′′ -debromohamacanthin A. They exhibited MICs of 4 -32 mg/L for MSSA and MRSA, 1 -32 mg/L for P. vulgaris and 4 -64 mg/L for S. enterica Typhimurium. 19, 38 During the synthesis of some of those marine bis-indole alkaloids, we obtained some mono-indolic compounds displaying good antibacterial activities against Staphylococcus species, with MICs of 8 -32 mg/L for the most active compounds. This MIC of the bis-indole compounds tested that could restore the bacteriostatic activity of ciprofloxacin used at 1, 2 or 4 mg/L against SA-1199B (MIC of ciprofloxacin¼16 mg/L).
Antibacterial evaluation of bis-indolic derivatives 1733 JAC activity was maintained against MDR MRSA and VISA strains. 22 SAR studies highlighted the importance of the presence of a halogen atom at position C-5 or C-6 of the indole core and of the ethanamine side chain (-CH 2 NH 2 or -CH 2 NHBoc) for the antibacterial activity. 22 Using a disconnection approach, further synthetic developments of bis-indole alkaloids from 1-(1H-indol-3-yl) ethanamine derivatives led to a set of bis-indolic compounds with either a central amide or a-keto-amide linker. 20 -22 In the present study, we have demonstrated that these compounds display potent activities against S. aureus and CoNS species with the lead compounds having MICs of 1-4 mg/L. Moreover, the antistaphylococcal activity of the bis-indolic compounds was not altered by common Staphylococcus sp. resistance mechanisms, including resistance to methicillin (through the mecA gene encoding PBP2a), glycopeptides (VISA strains) or fluoroquinolones (through NorA overexpression). The bis-indoles displayed a bactericidal effect against S. aureus strains after 8 h of exposure, although it was more pronounced for compounds 10a, 14a and 17d. However, after 8 h bacterial regrowth was observed. According to the CLSI M26-A guidelines, regrowth can be due to: (i) selection of resistant mutants; (ii) drug inactivation over time in incubated cultures; and (iii) bacterial adhesion to the glass tubes used in time -kill assays leading to artefactual growth of susceptible bacteria. 29 The first hypothesis was ruled out by demonstrating that 17d MICs were unchanged for surviving bacteria. Inactivation of the bis-indoles after 24 h of incubation at 378C also seems unlikely since a .3 log 10 reduction in cfu counts was observed in MBC experiments after the same incubation time. Therefore, the bacterial regrowth observed for time -kill experiments could be artefactual. Especially, the poor correlation between MBC and time -kill experiments at 24 h incubation time may be related to different experimental conditions, including very different reaction volumes and bacterial growth containers (polystyrene microplates versus glass tubes, respectively).
A preliminary SAR analysis showed that the concomitant presence of a bromine atom at the C-5, C-5 ′ , C-6 or C-6 ′ position of the indole cores and of the CH 2 NHBoc side chain in the linker made it possible to obtain antibacterial activities similar to those of the mono-indolic derivatives previously described. Replacement of the CH 2 NHBoc chain with a carboxylic acid, an ester, a methyl alcohol or an alkyl amide group decreased or abolished antibacterial activities. Compared with mono-indolic derivatives, the bis-indole compounds showed a substantial increase in antibacterial activities when one bromine atom was added to each of the two indole cores. Improved antistaphylococcal activity was obtained with two atoms of bromine, whereas the introduction of atoms of fluorine or chlorine in place of bromine atom(s) led to MICs being increased 2 -8-fold. Finally, we demonstrated the importance of the free nitrogen atom of the second indole core. Indeed, the N-methylated derivative was completely inactive. This could result from the loss of opportunities for hydrogen bonds between this amine function in the N-methylated derivative and its bacterial target, likely necessary to inhibit bacterial growth. It was also surprising to note that the replacement of the CH 2 NHBoc side chain by a methyl group did not alter the antibacterial activity of the synthetic di-brominated bis-indole compounds. Further structural optimizations are still required, however, to improve their solubility at physiological pH, to obtain a higher fraction of unbound compound and to reduce their cytotoxicity while enhancing their antibacterial activity. The mechanism(s) of action and bacterial target(s) of our bis-indole derivatives have not yet been elucidated, but a number of hypotheses can be highlighted. In the literature, a few molecules with a bis-indole scaffold (other than natural marine bis-indole alkaloids) are mentioned as antibacterial agents, including bis-(imidazolinylindole) derivatives with broad-spectrum antibacterial activity against Gram-positive (i.e. Staphylococcus, Enterococcus, Streptococcus and Clostridium species) and Gram-negative (i.e. Enterobacteriaceae, Acinetobacter, Pseudomonas, Burkholderia and Haemophilus species) bacteria 39, 40 and bis-indoles active against MDR bacteria such as MRSA and vancomycin-resistant Enterococcus species, 39, 40 Mycobacterium tuberculosis 41 and Acinetobacter baumannii. 42 Sharing some structural features with molecules that bind to the minor groove of duplex DNA, these compounds may act through DNA synthesis inhibition with higher affinity for bacterial DNA than for mammalian DNA. 39 However, their rapid bactericidal effect, broad-spectrum activity and planar structure able to bind DNA probably indicate a different mechanism of action as compared with our bis-indole compounds. In another study, aryl-3,3
′ -bis(indolyl)methanes displaying weak antibacterial activity have been described, with no mention of their potential mechanism of action. 43 Very recently, antibacterial activity against E. coli and B. subtilis of synthetic bis-indole molecules with -CO-NH-NH-CO-and -CO-CO-NH-NH-CO-linkers was identified. They inhibit the interaction between RNA polymerase and s factors, which is essential to initiate bacterial transcription properly and efficiently. 44 As for the mode of action of the bis-indole compounds isolated from marine sponges, the first hypothesis focused on inhibition of virulence-associated protein sortase A (SrtA), a membraneassociated transpeptidase modulating the adhesion ability of S. aureus to host tissue. 45 However, in 2011, Zoraghi et al.
38
demonstrated that SrtA is not essential for the growth and viability of S. aureus and that specific SrtA inhibitors did not reduce bacterial growth. They also identified spongotine A, cis-3,4-dihydrohamacanthin B and bromodeoxytopsentin isolated from Topsentia pachastrelloides as potent inhibitors of MRSA pyruvate kinase (PK), an essential hub in the MRSA interactome and thus an advantageous target for development of new therapeutics. 38, 46 Measured IC 50 values were under the nanomolar level for MRSA PK and compounds displayed ≥166-600-fold selectivity towards bacterial versus human PK isoforms, owing to structural differences in protein sequences and structures. 38, 43, 46, 47 Cocrystallization of MRSA PK with inhibitor molecules located the binding pocket in a small interface of the PK tetramer. Through salt bridges and hydrophobic interactions, bis-indole compounds may block PK in a rigid conformation, preventing the enzyme from passing from its inactive to active state. 38, 46, 47 Evidence that our synthetic bis-indole derivatives may share the same antibacterial mechanism as the bis-indole alkaloids of sponges (i.e. inhibit MRSA PK) is also highlighted by the antistaphylococcal spectra and the structural similarities observed between compounds presented in this study and the previously identified MRSA PK inhibitors. 46, 48, 49 On the other hand, various observations require clarification: e.g. Zoraghi et al. 38 reported that bromotopsentin did not inhibit MRSA PK, although its activity against MRSA strains was described by Oh et al. 19 as similar to or 2-fold higher than that of bromodeoxytopsentin, a compound described as a potent MRSA PK inhibitor. 38 Moreover, in 2012, Kumar et al. 49 Caspar et al.
synthesized chemical compounds with high antistaphylococcal activity despite weak inhibition properties against MRSA PK, possibly because of their particular Z-configuration, and concluded that there was a poor correlation between anti-MRSA and PK inhibitory activities. This was also highlighted in a more recent paper from Kumar et al., 48 who developed compounds with low IC 50 against MRSA PK but high MICs. The authors suggested that the poor correlation between MRSA PK inhibitory activity and MIC values for S. aureus may be due to differences in solubility, cellular penetration or efflux of their bis-indole compounds. 48 The authors also demonstrated that the bactericidal activity of their lead compounds was dependent on the presence of the pyk gene in the tested bacterial strain but did not require PK metabolic activity. A bacteriostatic activity was preserved against an S. aureus strain in which the pyk gene had been deleted.
We recently demonstrated that some of our lead bis-indole compounds are also active against Francisella tularensis subsp. holarctica, 50 a highly virulent, facultative intracellular, Gramnegative bacillus. Therefore, the antibacterial spectrum of these compounds may not be limited to Staphylococcus species. The mode of action of the bis-indole compounds, either natural or synthetic, still has to be fully characterized. It can be hypothesized that these compounds block MRSA PK in an inactive state, but also alter non-enzymatic functions of this hub protein. Alternatively, there may be another bacterial target explaining pyk-independent bacteriostatic activity. It should be emphasized that SAR studies should be conducted on the basis of MIC values and not on the basis of the IC 50 for MRSA PK.
Bacterial resistance to fluoroquinolones is mainly related to mutations in the genes coding for DNA gyrase and topoisomerase IV, the natural targets of these antibiotics, and/or to overexpression of multidrug efflux pumps. 28, 51, 52 In the latter case, efflux pump inhibitors (EPIs) can partially restore the activity of the fluoroquinolones. Moreover, EPIs can reduce the emergence of fluoroquinolone-resistant mutants. 51 Characterization of new EPIs is mainly based on high-throughput screening of existing chemical libraries. Some of our synthetic bis-indole compounds displayed no proper antibacterial activity, but high inhibitory properties, against the multidrug efflux pump NorA, a member of the major facilitator superfamily whose overexpression plays a major role in fluoroquinolone resistance in S. aureus. To our knowledge, the structure of the NorA efflux pump has not been resolved, but this protein is considered to present a large hydrophobic binding site. 28 Previous indole-containing NorA EPIs have been described, including reserpine and 5-nitro-2-phenyl-1H-indole (INF55). The latter has recently been combined with berberine in a single molecule resulting in a .382-fold increase in berberine antibacterial activity against the NorA-overexpressing S. aureus strain SA-K2378. 53 We previously demonstrated that mono-indolic aldonitrones carrying a halogen atom at the C-5 position and a CH 2 NHBoc alkyl chain were potent NorA EPIs, with an activity 4 -5-fold higher than that of the reference compound reserpine. 23 In this study, we observed a 4-fold reduction of the ciprofloxacin MIC when adding one of the most active bis-indole compounds 9a or 12 at 0.5 and 1 mg/L, respectively. The restoration of the activity of ciprofloxacin was proportional to the concentration of the bis-indole derivative tested, confirming a synergistic effect between the two compounds. The combination of a fluoroquinolone and a bis-indole NorA-EPI may represent an advantageous therapeutic alternative for infections caused by NorA-overexpressing S. aureus strains. This combination may also better prevent the clinical emergence of high-level fluoroquinolone-resistant strains. The bis-indole derivatives with proper antibacterial activity could not be tested for potential NorA EPI activity, but these compounds may cumulate both properties. The present results correlate with those of Kumar et al., 48 which showed that the MIC of some of their bis-indole compounds was reduced 4 -32-fold for S. aureus when adding verapamil (an inhibitor of the ABC class of efflux pumps) at 200 mg/L to the culture medium. This suggests that the bis-indole compounds and verapamil are substrates of the same efflux pumps. The activation of such efflux pumps may explain why the bis-indole compounds are only transiently bactericidal against S. aureus in vitro.
In contrast to mono-indole EPIs, the SAR studies for bis-indole NorA EPIs did not show better antibacterial activity when a halogen was added at any position on the indole core, as observed for EPI compounds 9a and 12. Moreover, the acidic function of EPI 14b correlated with a strong loss of NorA EPI potency. This was probably related to the introduction of a negative charge via deprotonation of the acidic function, no longer fitting with the hydrophobic pocket of the active site of the NorA efflux pump. Further ethidium bromide efflux inhibition assays will enable us to compare the inhibition potency of our lead EPIs with other potent NorA EPIs.
In conclusion, we synthesized bis-indolic compounds with original structures as compared with the natural bis-indole alkaloids of marine sponges. Among them, we identified derivatives with antistaphylococcal properties, including against MRSA and VISA strains, but also derivatives with inhibitory activity against the S. aureus NorA efflux pump. All these derivatives are promising candidates for development of new antistaphylococcal treatments that are active against MDR S. aureus. The bacterial target(s) of these bis-indolic compounds remains to be characterized. Further structural optimization is needed to tentatively increase the solubility and activity of these compounds and reduce their cytotoxicity.
